Efficacy and Safety of 3D-Printed PEEK Skull Implants in Cranioplasty

January 16, 2025 updated by: CIMET SCIENTIFIC CORPORATION

Efficacy and Safety of Customized Skull Implants Made of Polyetheretheretherketone Using Three-dimensional Printing in Patients Undergoing Cranioplasty

The goal of this clinical trial is to determine the efficacy and safety of customized skull implants made of polyetheretheretherketone by three-dimensional printing in patients undergoing cranioplasty. The main question it aims to answer is:

• Are customized skull implants made of polyetheretheretherketone using 3D printing effective and safe in patients undergoing cranioplasty?

Participants will:

  • The patient will be submitted to cranioplasty.
  • The patient will answer the neurological scales at each visit.
  • Keep a diary of their symptoms and concomitant medications
  • The study will be divided into 5 visits to the center, the surgical intervention and 3 telephone calls where patients will be followed up.

Study Overview

Detailed Description

The aim of this study is to evaluate the efficacy and safety of personalized skull implants made of polyetheretheretherketone (PEEK) using three-dimensional printing in patients undergoing cranioplasty. This is a phase II clinical trial, with a single group of 30 patients who have suffered cranial bone loss. Specific objectives include analyzing the incidence of complications (infections, fractures, implant exposure), assessing functional recovery using recognized scales such as the Glasgow and Barthel scales, and measuring patient and surgeon aesthetic satisfaction over 12 months.

The design includes multiple follow-up visits, from surgery to one year after, where neurological, functional and cosmetic assessments will be performed.

The selection and exclusion criteria ensure the suitability of the participants, while the variables monitored allow a comprehensive analysis of the results, from cognitive functionality to surgical complications. This study seeks to provide scientific evidence to support the implementation of this technology in patients with cranial defects, improving both quality of life and post-surgical aesthetic and functional outcomes.

-Main inclusion criteria: Being older than 18 years, of both sexes. Loss of cranial bone segment greater than 1 cm². Glasgow Coma Scale (GCS) score equal or greater than 9. Satisfactory pre-surgical evaluation. Signed informed consent.

-Main exclusion criteria: Local infection at the craniotomy site or active systemic infection. Presence of previous surgical instruments at the cranioplasty site. Need to use two or more implants for reconstruction. History of coagulopathies, uncontrolled diabetes mellitus or body mass index (BMI) greater than 35.

Pregnant or lactating women.

-Main variables: Efficacy and safety: frequency of complications such as infections, fractures and implant exposure.

Cognitive functionality: Assessed by the Mini-Mental State Examination (MMSE). Functional independence: Measured with the Barthel index. Degree of disability: Assessed with the Modified Rankin Scale (mRS). Cosmetic satisfaction: Patient and surgeon satisfaction. Adverse events: Incidence during the 12 months of follow-up.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Jalisco
      • Guadalajara, Jalisco, Mexico, 44340
        • Centro de Investigación Clínica y Medicina Traslacional (CIMeT)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adults >18 years old.
  • Both sexes.
  • Who agree to participate and sign the informed consent form.
  • With loss of a bone segment.
  • Area of bone segment loss greater than 1 cm.
  • Glasgow Coma Scale score equal to or greater than 9.
  • Satisfactory preoperative evaluation

Exclusion Criteria:

  • Presence of local infection at the craniotomy site or any type of systemic infection at the time of medical evaluation and systemic infection at the time of medical evaluation and during surgery.
  • Presence of previous surgical instruments in the cranioplasty site.
  • Need to use two or more implants for the reconstruction.
  • The resulting angle between the tangential lines to the curvature of the implant and the tangent determined to the center of the implant, determined to the center of the implant, is greater than 50º.
  • Patients whose cranial morphology presents difficulties for the prosthesis design.
  • Presence of postoperative ossifications in the defect area.
  • History of hypersensitivity to biomaterials.
  • Surgery at the same site within the 6 months prior to the study surgery.
  • Patients with any diagnosis that affects blood supply and bone quality.
  • Patients who have received chemotherapy or radiotherapy in the surgical region that ended within 6 months prior to the planned surgery or are scheduled for the next 12 weeks.
  • Diagnosis of malignant cranial tumor.
  • History of any status epilepticus.
  • Known history of hemophilia or other clinically significant coagulopathy.
  • Patients with uncontrolled diabetes according to, ADA criteria:

    o fasting glucose ≥ 200 mg/dL, HbA1C ≥ 8.5% in the last 3 months.

  • Patients with a body mass index (BMI) ≥ 35 kg/m
  • History of steroid drugs at least 3 months before surgery.
  • Women breastfeeding or pregnant.
  • Inability to read and understand the participant's information.
  • Prior participation in any related investigational drug or device study within 30 days.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: cranioplasty using customized skull implants made of polyetheretheretherketone using 3D printing
All participants will undergo cranioplasty using customized skull implants made of polyetheretheretherketone using 3D printing
In this pivotal study of a medical device, patients with bone loss undergo a computed tomography scan, which is used to create a three-dimensional model of the lesion. After validation, the model is printed using PEEK material, and subsequently, the skull is repaired through cranial reconstruction (cranioplasty).
customized skull implants made of polyetheretheretherketone by three-dimensional printing in patients undergoing cranioplasty

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Frequency and causes of cranioplasty revisions
Time Frame: From enrollment to the end of treatment at 12 months
Cranioplasty revision is performed when it is necessary to correct or adjust a previously placed implant, either due to complications adjust a previously placed implant, either due to complications, lack of integration of the implant or changes in the desired form and function.
From enrollment to the end of treatment at 12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Infection at the implant site
Time Frame: From enrollment to 3 months after surgery
Evaluate the frequency of infection at the implant site after cranioplasty.
From enrollment to 3 months after surgery
Frequency of surgery-associated infections
Time Frame: From enrollment to 3 months after surgery
These are infections that develop as a direct result of a surgical procedure. These infections can affect various parts of the body and are not necessarily limited to the implant site.
From enrollment to 3 months after surgery
Frequency of implant exposure
Time Frame: From enrollment to the end of treatment at 12 months
It refers to the fact that the implants placed in the cranial region, in reconstructive or reparative surgeries of the skull, are visible or accessible in some way.
From enrollment to the end of treatment at 12 months
Frequency and type of implant fractures
Time Frame: From enrollment to the end of treatment at 12 months
Refers to the rupture or cracking of devices implanted in the cranial region, used in reconstructive or reparative surgeries of the skull.
From enrollment to the end of treatment at 12 months
Level of consciousness
Time Frame: From enrollment to 3 months after surgery
Establish the level of consciousness with the Glasgow Coma Scale (GCS).
From enrollment to 3 months after surgery
Cognitive function
Time Frame: From enrollment to the end of treatment at 12 months
Measure cognitive function with the Mini-Mental State Examination (MMSE).
From enrollment to the end of treatment at 12 months
Functional independence
Time Frame: From enrollment to the end of treatment at 12 months
Evaluate functional independence with the Barthel Index.
From enrollment to the end of treatment at 12 months
Level of disability
Time Frame: From enrollment to the end of treatment at 12 months
Evaluate the degree of disability with the modified Rankin Scale (mRS).
From enrollment to the end of treatment at 12 months
Cosmetic satisfaction
Time Frame: From enrollment to the end of treatment at 12 months
Subjective scale to assess patient and surgeon satisfaction in terms of aesthetic and functional results after cranioplasty surgery.
From enrollment to the end of treatment at 12 months
Frequency of adverse incidents
Time Frame: From enrollment to the end of treatment at 12 months
From enrollment to the end of treatment at 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Geannyne Villegas Rivera, MD, PhD, MBA, Centro de Investigación Clínica y Medicina Traslacional (CIMeT)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2025

Primary Completion (Estimated)

October 1, 2025

Study Completion (Estimated)

September 1, 2026

Study Registration Dates

First Submitted

January 8, 2025

First Submitted That Met QC Criteria

January 16, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 16, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

The decision to share IPD is currently 'Undecided' because further discussions and evaluations are needed regarding the feasibility, ethical considerations, and alignment with institutional policies. Once these factors are thoroughly assessed, a final determination will be made.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cranial Defects

Clinical Trials on cranioplasty

Subscribe